Table 3. Univariate and multivariate analyses of the impact on survival of clinical features along with logged CRP, IL-6 and GM-CSF levels.
| Univariate | Hazard ratio (95% CI) | P-value |
|---|---|---|
| Response: PD v SD/PR | 8.61 (2.97–24.98) | <0.0001 |
| Age | 0.98 (0.95–1.02) | 0.40 |
| Stage: locally advanced vs metastatic | 0.66 (0.32–1.37) | 0.26 |
| ECOG 0 v 1 | 1.02 (0.45–2.28) | |
| ECOG 1 v 2 | 0.42 (0.14–1.26) | 0.22 |
| ECOG 0 v 2 | 0.41 (0.15–1.17) | |
| Log CA19-9: baseline | 1.33 (1.10–1.61) | 0.004 |
| Log CRP: baseline | 1.76 (1.18–2.65) | 0.006 |
| Log CRP: post treatment | 1.38 (0.89–2.13) | 0.16 |
| Log CRP: difference | 0.75 (0.46–1.23) | 0.25 |
| Log IL-6: baseline | 0.73 (0.47–1.14) | 0.16 |
| Log IL-6: post treatment | 0.84 (0.61–1.15) | 0.27 |
| Log Il-6: difference | 1.05 (0.64–1.75) | 0.84 |
| GM-CSF: baseline | 0.75 (0.33–1.71) | 0.50 |
| GM-CSF: post treatment | 0.81 (0.36–1.81) | 0.60 |
|
Multivariate | ||
| Log CA19-9: baseline | 1.30 (1.07–1.59) | 0.009 |
| Log CRP: baseline | 1.55 (1.00–2.39) | 0.049 |
Abbreviations: CA19-9=carbohydrate antigen-19-9; CI=confidence interval; CRP=C-reactive protein; ECOG=Eastern Cooperative Oncology Group; GM-CSF=granulocyte macrophage-colony-stimulating factor; IL-6=interleukin 6; PD=progressive disease; PR=partial response; SD=stable disease. The bold values are statistically significant.